{
  "meta": {
    "data_length": 2,
    "message": "Statements retrieved successfully",
    "request_url": "http://api.moalmanac.org/statements?proposition_id=534&agent_id=fda&agent_id=ema&agent_id=hse&agent_id=hpra",
    "status": "success",
    "status_code": 200,
    "timestamp_elapsed": 0.025868,
    "timestamp_received": "2026-09-07T20:38:13.483109+00:00Z",
    "timestamp_returned": "2026-09-07T20:38:13.508977+00:00Z",
    "trace_id": "83c2987a-6937-4595-8ccf-bf82ee063eac"
  },
  "service": {
    "github": "https://github.com/vanallenlab/moalmanac-db",
    "name": "Molecular Oncology Almanac",
    "license": "GPL-2.0",
    "release": "draft",
    "url": "https://dev.moalmanac.org",
    "last_updated": "2026-05-07"
  },
  "data": [
    {
      "id": 649,
      "type": "Statement",
      "description": "The European Medicines Agency (EMA) has authorized brentuximab vedotin for the treatment of adult patients with CD30+ cutaneous T-cell lymphoma (CTCL) after at least 1 prior systemic therapy.",
      "contributions": [
        {
          "id": 13,
          "type": "Contribution",
          "agent": {
            "id": "vanallenlab",
            "type": "Agent",
            "agentType": "contributor",
            "name": "Van Allen lab",
            "description": "Van Allen lab, Dana-Farber Cancer Institute",
            "last_updated": null,
            "url": null
          },
          "description": "Adding EMA approvals for use to database",
          "date": "2024-10-20"
        }
      ],
      "reportedIn": [
        {
          "id": "doc:ema.adcetris",
          "type": "Document",
          "documentType": "Regulatory approval",
          "name": "Adcetris (brentuximab vedotin) [product information]. EMA.",
          "title": null,
          "aliases": [],
          "description": "Takeda Pharma A/S. Adcetris (brentuximab vedotin) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/adcetris-epar-product-information_en.pdf. Revised December 2023. Accessed March 11, 2024.",
          "urls": [
            "https://www.ema.europa.eu/en/medicines/human/EPAR/adcetris",
            "https://www.ema.europa.eu/en/documents/product-information/adcetris-epar-product-information_en.pdf"
          ],
          "doi": null,
          "pmid": null,
          "extensions": [
            {
              "name": "agent",
              "value": {
                "id": "ema",
                "type": "Agent",
                "agentType": "organization",
                "name": "European Medicines Agency",
                "description": "Regulatory agency that approves medicines for use in the European Union.",
                "extensions": [
                  {
                    "name": "last_updated",
                    "value": "2026-05-05",
                    "description": ""
                  },
                  {
                    "name": "url",
                    "value": "https://www.ema.europa.eu/en/medicines",
                    "description": ""
                  }
                ]
              },
              "description": "The organization that published this document."
            },
            {
              "name": "company",
              "value": "Takeda Pharma A/S.",
              "description": "The company that manufactures the cancer drug. Only applicable to market authorization documents."
            },
            {
              "name": "drug_name_brand",
              "value": "Adcetris",
              "description": "The brand name of the cancer drug, per this document. Only applicable to market authorization documents."
            },
            {
              "name": "drug_name_generic",
              "value": "brentuximab vedotin",
              "description": "The generic name of the cancer drug, per this document. Only applicable to market authorization documents."
            },
            {
              "name": "first_publication_date",
              "value": "2012-11-22",
              "description": "The publication date for the initial version of this document."
            },
            {
              "name": "identification_number",
              "value": null,
              "description": "Identification number used by the publishing organization."
            },
            {
              "name": "publication_date",
              "value": "2023-12-01",
              "description": "The publication date for the document."
            },
            {
              "name": "status",
              "value": "Active",
              "description": "Whether this document is Active or Deprecated within moalmanac-db."
            }
          ]
        }
      ],
      "direction": "supports",
      "indication": {
        "id": "ind:ema.adcetris:3",
        "indication": "ADCETRIS is indicated for the treatment of adult patients with CD30+ cutaneous T-cell lymphoma (CTCL) after at least 1 prior systemic therapy.",
        "initial_approval_date": "2017-12-15",
        "initial_approval_url": "https://www.ema.europa.eu/en/documents/variation-report/adcetris-h-c-002455-ii-0048-epar-assessment-report-variation_en.pdf",
        "description": "The European Medicines Agency (EMA) has authorized brentuximab vedotin for the treatment of adult patients with CD30+ cutaneous T-cell lymphoma (CTCL) after at least 1 prior systemic therapy.",
        "raw_biomarkers": null,
        "raw_cancer_type": "Cutaneous T-cell lymphoma (CTCL)",
        "raw_therapeutics": "Adcetris (brentuximab vedotin)",
        "icd10": null,
        "regimen_code": null,
        "reimbursement_category": null,
        "reimbursement_date": null,
        "reimbursement_details": null,
        "date_regular_approval": null,
        "date_accelerated_approval": null,
        "document": {
          "id": "doc:ema.adcetris",
          "type": "Document",
          "documentType": "Regulatory approval",
          "name": "Adcetris (brentuximab vedotin) [product information]. EMA.",
          "title": null,
          "aliases": [],
          "description": "Takeda Pharma A/S. Adcetris (brentuximab vedotin) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/adcetris-epar-product-information_en.pdf. Revised December 2023. Accessed March 11, 2024.",
          "urls": [
            "https://www.ema.europa.eu/en/medicines/human/EPAR/adcetris",
            "https://www.ema.europa.eu/en/documents/product-information/adcetris-epar-product-information_en.pdf"
          ],
          "doi": null,
          "pmid": null,
          "extensions": [
            {
              "name": "agent",
              "value": {
                "id": "ema",
                "type": "Agent",
                "agentType": "organization",
                "name": "European Medicines Agency",
                "description": "Regulatory agency that approves medicines for use in the European Union.",
                "extensions": [
                  {
                    "name": "last_updated",
                    "value": "2026-05-05",
                    "description": ""
                  },
                  {
                    "name": "url",
                    "value": "https://www.ema.europa.eu/en/medicines",
                    "description": ""
                  }
                ]
              },
              "description": "The organization that published this document."
            },
            {
              "name": "company",
              "value": "Takeda Pharma A/S.",
              "description": "The company that manufactures the cancer drug. Only applicable to market authorization documents."
            },
            {
              "name": "drug_name_brand",
              "value": "Adcetris",
              "description": "The brand name of the cancer drug, per this document. Only applicable to market authorization documents."
            },
            {
              "name": "drug_name_generic",
              "value": "brentuximab vedotin",
              "description": "The generic name of the cancer drug, per this document. Only applicable to market authorization documents."
            },
            {
              "name": "first_publication_date",
              "value": "2012-11-22",
              "description": "The publication date for the initial version of this document."
            },
            {
              "name": "identification_number",
              "value": null,
              "description": "Identification number used by the publishing organization."
            },
            {
              "name": "publication_date",
              "value": "2023-12-01",
              "description": "The publication date for the document."
            },
            {
              "name": "status",
              "value": "Active",
              "description": "Whether this document is Active or Deprecated within moalmanac-db."
            }
          ]
        }
      },
      "proposition": {
        "id": 534,
        "type": "VariantTherapeuticResponseProposition",
        "predicate": "predictSensitivityTo",
        "biomarkers": [
          {
            "id": 0,
            "name": "CD30 +",
            "genes": [],
            "type": "CategoricalVariant",
            "extensions": [
              {
                "name": "biomarker_type",
                "value": "Protein expression"
              },
              {
                "name": "present",
                "value": true
              },
              {
                "name": "marker",
                "value": "CD30"
              },
              {
                "name": "unit",
                "value": "status"
              },
              {
                "name": "equality",
                "value": "="
              },
              {
                "name": "value",
                "value": "Positive"
              }
            ]
          }
        ],
        "subjectVariant": {},
        "conditionQualifier": {
          "id": 30,
          "conceptType": "Disease",
          "name": "Cutaneous T-cell Lymphoma",
          "primaryCoding": {
            "id": "ncit:C3467",
            "code": "C3467",
            "name": "Primary Cutaneous T-Cell Non-Hodgkin Lymphoma",
            "system": "https://evsexplore.semantics.cancer.gov",
            "systemVersion": "25.01d",
            "iris": [
              "https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C3467"
            ]
          },
          "mappings": []
        },
        "objectTherapeutic": {
          "id": 0,
          "conceptType": "Drug",
          "name": "Brentuximab vedotin",
          "primaryCoding": {
            "id": "ncit:C66944",
            "code": "C66944",
            "name": "Brentuximab Vedotin",
            "system": "https://evsexplore.semantics.cancer.gov",
            "systemVersion": "25.01d",
            "iris": [
              "https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C66944"
            ]
          },
          "mappings": [
            {
              "relation": "relatedMatch",
              "coding": {
                "id": "rxcui:1147320",
                "code": "1147320",
                "name": "brentuximab vedotin",
                "system": "RxNorm",
                "systemVersion": "20250602",
                "iris": [
                  "https://mor.nlm.nih.gov/RxNav/search?searchBy=RXCUI&searchTerm=1147320"
                ]
              }
            },
            {
              "relation": "relatedMatch",
              "coding": {
                "id": "omop:37017170",
                "code": "37017170",
                "name": "Brentuximab vedotin",
                "system": "OMOP",
                "systemVersion": "v20250827",
                "iris": [
                  "https://athena.ohdsi.org/search-terms/terms/37017170"
                ]
              }
            },
            {
              "relation": "relatedMatch",
              "coding": {
                "id": "sctid:713395006",
                "code": "713395006",
                "name": "Brentuximab vedotin",
                "system": "SNOMED",
                "systemVersion": "2025-03-01",
                "iris": [
                  "https://browser.ihtsdotools.org/?perspective=full&conceptId1=713395006&edition=MAIN/2025-03-01&release=&languages=en"
                ]
              }
            },
            {
              "relation": "relatedMatch",
              "coding": {
                "id": "omop:40241969",
                "code": "40241969",
                "name": "brentuximab vedotin",
                "system": "OMOP",
                "systemVersion": "v20250827",
                "iris": [
                  "https://athena.ohdsi.org/search-terms/terms/40241969"
                ]
              }
            }
          ],
          "extensions": [
            {
              "name": "therapy_strategy",
              "value": [
                "target CD30 antigens"
              ],
              "description": "Associated therapeutic strategy or mechanism of action of the therapy."
            },
            {
              "name": "therapy_type",
              "value": "Targeted therapy",
              "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"
            }
          ]
        }
      }
    },
    {
      "id": 1317,
      "type": "Statement",
      "description": "The Republic of Ireland's Health Service Executive (HSE) has approved brentuximab vedotin for reimbursement as a treatment option for the treatment of adult patients with CD30+ cutaneous T-cell lymphoma (CTCL) after at least 1 prior systemic therapy.",
      "contributions": [
        {
          "id": 41,
          "type": "Contribution",
          "agent": {
            "id": "vanallenlab",
            "type": "Agent",
            "agentType": "contributor",
            "name": "Van Allen lab",
            "description": "Van Allen lab, Dana-Farber Cancer Institute",
            "last_updated": null,
            "url": null
          },
          "description": "Adding HSE approvals for reimbursement to database",
          "date": "2024-01-16"
        }
      ],
      "reportedIn": [
        {
          "id": "doc:hse.00234",
          "type": "Document",
          "documentType": "Regulatory approval",
          "name": "Brentuximab vedotin Monotherapy. NCCP National SACT Regimen. HSE.",
          "title": null,
          "aliases": [],
          "description": "Brentuximab vedotin Monotherapy, 2025, version number 6, NCCP National SACT Regimen, NCCP, viewed 26/03/2026, https://healthservice.hse.ie/documents/6333/234_v6_Brentuximab.pdf",
          "urls": [
            "https://healthservice.hse.ie/documents/6333/234_v6_Brentuximab.pdf"
          ],
          "doi": null,
          "pmid": null,
          "extensions": [
            {
              "name": "agent",
              "value": {
                "id": "hse",
                "type": "Agent",
                "agentType": "organization",
                "name": "Health Service Executive",
                "description": "Regulatory agency that approves medicines for reimbursement by the public health system in the Republic of Ireland.",
                "extensions": [
                  {
                    "name": "last_updated",
                    "value": "2025-10-01",
                    "description": ""
                  },
                  {
                    "name": "url",
                    "value": "https://healthservice.hse.ie/staff/information-healthcare-workers/nccp/national-sact-regimens/",
                    "description": ""
                  }
                ]
              },
              "description": "The organization that published this document."
            },
            {
              "name": "company",
              "value": "",
              "description": "The company that manufactures the cancer drug. Only applicable to market authorization documents."
            },
            {
              "name": "drug_name_brand",
              "value": null,
              "description": "The brand name of the cancer drug, per this document. Only applicable to market authorization documents."
            },
            {
              "name": "drug_name_generic",
              "value": null,
              "description": "The generic name of the cancer drug, per this document. Only applicable to market authorization documents."
            },
            {
              "name": "first_publication_date",
              "value": null,
              "description": "The publication date for the initial version of this document."
            },
            {
              "name": "identification_number",
              "value": null,
              "description": "Identification number used by the publishing organization."
            },
            {
              "name": "publication_date",
              "value": "2022-12-20",
              "description": "The publication date for the document."
            },
            {
              "name": "status",
              "value": "Active",
              "description": "Whether this document is Active or Deprecated within moalmanac-db."
            }
          ]
        }
      ],
      "direction": "supports",
      "indication": {
        "id": "ind:hse.00234:d",
        "indication": "Treatment of adult patients with CD30+ cutaneous T-cell lymphoma (CTCL) after at least 1 prior systemic therapy",
        "initial_approval_date": "2022-12-01",
        "initial_approval_url": null,
        "description": "The Republic of Ireland's Health Service Executive (HSE) has approved brentuximab vedotin for reimbursement as a treatment option for the treatment of adult patients with CD30+ cutaneous T-cell lymphoma (CTCL) after at least 1 prior systemic therapy.",
        "raw_biomarkers": "CD30+",
        "raw_cancer_type": "Cutaneous T-cell lymphoma (CTCL)",
        "raw_therapeutics": "Brentuximab vedotin",
        "icd10": null,
        "regimen_code": null,
        "reimbursement_category": null,
        "reimbursement_date": null,
        "reimbursement_details": null,
        "date_regular_approval": null,
        "date_accelerated_approval": null,
        "document": {
          "id": "doc:hse.00234",
          "type": "Document",
          "documentType": "Regulatory approval",
          "name": "Brentuximab vedotin Monotherapy. NCCP National SACT Regimen. HSE.",
          "title": null,
          "aliases": [],
          "description": "Brentuximab vedotin Monotherapy, 2025, version number 6, NCCP National SACT Regimen, NCCP, viewed 26/03/2026, https://healthservice.hse.ie/documents/6333/234_v6_Brentuximab.pdf",
          "urls": [
            "https://healthservice.hse.ie/documents/6333/234_v6_Brentuximab.pdf"
          ],
          "doi": null,
          "pmid": null,
          "extensions": [
            {
              "name": "agent",
              "value": {
                "id": "hse",
                "type": "Agent",
                "agentType": "organization",
                "name": "Health Service Executive",
                "description": "Regulatory agency that approves medicines for reimbursement by the public health system in the Republic of Ireland.",
                "extensions": [
                  {
                    "name": "last_updated",
                    "value": "2025-10-01",
                    "description": ""
                  },
                  {
                    "name": "url",
                    "value": "https://healthservice.hse.ie/staff/information-healthcare-workers/nccp/national-sact-regimens/",
                    "description": ""
                  }
                ]
              },
              "description": "The organization that published this document."
            },
            {
              "name": "company",
              "value": "",
              "description": "The company that manufactures the cancer drug. Only applicable to market authorization documents."
            },
            {
              "name": "drug_name_brand",
              "value": null,
              "description": "The brand name of the cancer drug, per this document. Only applicable to market authorization documents."
            },
            {
              "name": "drug_name_generic",
              "value": null,
              "description": "The generic name of the cancer drug, per this document. Only applicable to market authorization documents."
            },
            {
              "name": "first_publication_date",
              "value": null,
              "description": "The publication date for the initial version of this document."
            },
            {
              "name": "identification_number",
              "value": null,
              "description": "Identification number used by the publishing organization."
            },
            {
              "name": "publication_date",
              "value": "2022-12-20",
              "description": "The publication date for the document."
            },
            {
              "name": "status",
              "value": "Active",
              "description": "Whether this document is Active or Deprecated within moalmanac-db."
            }
          ]
        }
      },
      "proposition": {
        "id": 534,
        "type": "VariantTherapeuticResponseProposition",
        "predicate": "predictSensitivityTo",
        "biomarkers": [
          {
            "id": 0,
            "name": "CD30 +",
            "genes": [],
            "type": "CategoricalVariant",
            "extensions": [
              {
                "name": "biomarker_type",
                "value": "Protein expression"
              },
              {
                "name": "present",
                "value": true
              },
              {
                "name": "marker",
                "value": "CD30"
              },
              {
                "name": "unit",
                "value": "status"
              },
              {
                "name": "equality",
                "value": "="
              },
              {
                "name": "value",
                "value": "Positive"
              }
            ]
          }
        ],
        "subjectVariant": {},
        "conditionQualifier": {
          "id": 30,
          "conceptType": "Disease",
          "name": "Cutaneous T-cell Lymphoma",
          "primaryCoding": {
            "id": "ncit:C3467",
            "code": "C3467",
            "name": "Primary Cutaneous T-Cell Non-Hodgkin Lymphoma",
            "system": "https://evsexplore.semantics.cancer.gov",
            "systemVersion": "25.01d",
            "iris": [
              "https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C3467"
            ]
          },
          "mappings": []
        },
        "objectTherapeutic": {
          "id": 0,
          "conceptType": "Drug",
          "name": "Brentuximab vedotin",
          "primaryCoding": {
            "id": "ncit:C66944",
            "code": "C66944",
            "name": "Brentuximab Vedotin",
            "system": "https://evsexplore.semantics.cancer.gov",
            "systemVersion": "25.01d",
            "iris": [
              "https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C66944"
            ]
          },
          "mappings": [
            {
              "relation": "relatedMatch",
              "coding": {
                "id": "rxcui:1147320",
                "code": "1147320",
                "name": "brentuximab vedotin",
                "system": "RxNorm",
                "systemVersion": "20250602",
                "iris": [
                  "https://mor.nlm.nih.gov/RxNav/search?searchBy=RXCUI&searchTerm=1147320"
                ]
              }
            },
            {
              "relation": "relatedMatch",
              "coding": {
                "id": "omop:37017170",
                "code": "37017170",
                "name": "Brentuximab vedotin",
                "system": "OMOP",
                "systemVersion": "v20250827",
                "iris": [
                  "https://athena.ohdsi.org/search-terms/terms/37017170"
                ]
              }
            },
            {
              "relation": "relatedMatch",
              "coding": {
                "id": "sctid:713395006",
                "code": "713395006",
                "name": "Brentuximab vedotin",
                "system": "SNOMED",
                "systemVersion": "2025-03-01",
                "iris": [
                  "https://browser.ihtsdotools.org/?perspective=full&conceptId1=713395006&edition=MAIN/2025-03-01&release=&languages=en"
                ]
              }
            },
            {
              "relation": "relatedMatch",
              "coding": {
                "id": "omop:40241969",
                "code": "40241969",
                "name": "brentuximab vedotin",
                "system": "OMOP",
                "systemVersion": "v20250827",
                "iris": [
                  "https://athena.ohdsi.org/search-terms/terms/40241969"
                ]
              }
            }
          ],
          "extensions": [
            {
              "name": "therapy_strategy",
              "value": [
                "target CD30 antigens"
              ],
              "description": "Associated therapeutic strategy or mechanism of action of the therapy."
            },
            {
              "name": "therapy_type",
              "value": "Targeted therapy",
              "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"
            }
          ]
        }
      }
    }
  ]
}